Watchlist Price Alert

Adaptive Biotechnologies ... (ADPT)

NASDAQ: ADPT · Real-Time Price · USD

8.81

0.00 (0.00%)

At close: May 07, 2025, 3:59 PM

8.90

0.96%

After-hours: May 07, 2025, 07:13 PM EDT

0.00% (1D)

Bid	8.25
Market Cap	1.31B
Revenue (ttm)	189.53M
Net Income (ttm)	-141.84M
EPS (ttm)	-0.95
PE Ratio (ttm)	-9.28
Forward PE	-12.6
Analyst	Buy

Ask	8.9
Volume	2,787,627
Avg. Volume (20D)	2,429,246
Open	9.04
Previous Close	8.81
Day's Range	8.38 - 9.11
52-Week Range	2.99 - 10.28
Beta	1.76

About ADPT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ADPT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ADPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Adaptive Biotechnologies has released their quartely earnings on May 1, 2025:

Revenue of $52.4M exceeds estimates by $10.27M, with 25.14% YoY growth.

EPS of -0.2 exceeds estimates by 0.11, with 39.39% YoY growth.

Why Price Moved

5 days ago

+33.7%

Adaptive Biotechnologies shares are trading higher... Unlock content with Pro Subscription

5 days ago

+0%

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q1 financial results.

News

6 days ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chi...

6 days ago · zacks.com

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal...

6 days ago · zacks.com

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Fou...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to ...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.